JP2020501550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501550A5 JP2020501550A5 JP2019531303A JP2019531303A JP2020501550A5 JP 2020501550 A5 JP2020501550 A5 JP 2020501550A5 JP 2019531303 A JP2019531303 A JP 2019531303A JP 2019531303 A JP2019531303 A JP 2019531303A JP 2020501550 A5 JP2020501550 A5 JP 2020501550A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- domain
- pharmaceutical composition
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 79
- 108020001507 fusion proteins Proteins 0.000 claims description 79
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 53
- 235000018102 proteins Nutrition 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 108020001580 protein domains Proteins 0.000 claims description 39
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 19
- 102000055277 human IL2 Human genes 0.000 claims description 15
- 210000003289 regulatory T cell Anatomy 0.000 claims description 14
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102220588600 Apolipoprotein C-IV_Q126L_mutation Human genes 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 101600101355 Mus musculus Interleukin-1 receptor-like 1 (isoform B) Proteins 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 102220622777 Sphingomyelin phosphodiesterase_N88G_mutation Human genes 0.000 claims description 4
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 102220273516 rs768267292 Human genes 0.000 claims description 4
- 102220097722 rs876660020 Human genes 0.000 claims description 4
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 208000004631 alopecia areata Diseases 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000006938 muscular dystrophy Diseases 0.000 claims description 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 239000000539 dimer Substances 0.000 description 14
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 description 6
- 102000045906 human IL33 Human genes 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433533P | 2016-12-13 | 2016-12-13 | |
| US62/433,533 | 2016-12-13 | ||
| PCT/US2017/066163 WO2018112069A1 (en) | 2016-12-13 | 2017-12-13 | Multivalent regulatory t cell modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501550A JP2020501550A (ja) | 2020-01-23 |
| JP2020501550A5 true JP2020501550A5 (cg-RX-API-DMAC7.html) | 2021-01-28 |
| JP7228515B2 JP7228515B2 (ja) | 2023-02-24 |
Family
ID=62488540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531303A Active JP7228515B2 (ja) | 2016-12-13 | 2017-12-13 | 多価制御性ｔ細胞調節因子 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10472405B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3554525A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7228515B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190094222A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110177564A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017378308A1 (cg-RX-API-DMAC7.html) |
| BR (2) | BR122020025384B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3044416A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX381276B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2769871C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018112069A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840545B2 (en) | 2013-09-20 | 2017-12-12 | University Of Virginia Patent Foundation | Fusion protein comprising interleukin-2 and interleukin-33 |
| JP7228515B2 (ja) | 2016-12-13 | 2023-02-24 | デリニア，インコーポレーテッド | 多価制御性ｔ細胞調節因子 |
| AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| RU2021105821A (ru) | 2018-08-06 | 2021-05-27 | Медикайн, Инк. | Соединения, связывающие рецептор il-2 |
| CN113286814A (zh) * | 2018-10-31 | 2021-08-20 | 德里尼亚公司 | 多价调节性t细胞调节子 |
| WO2020236875A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Therapeutics, Inc. | Madcam targeted immunotolerance |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| CN114853874B (zh) * | 2019-09-10 | 2024-05-17 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
| BR112022008750A2 (pt) | 2019-11-05 | 2022-07-19 | Medikine Inc | Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico |
| WO2021092075A1 (en) | 2019-11-05 | 2021-05-14 | Medikine Inc. | IL-2RβγC BINDING COMPOUNDS |
| WO2021158623A1 (en) | 2020-02-03 | 2021-08-12 | Medikine, Inc. | IL-7Rαγc BINDING COMPOUNDS |
| JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒα結合化合物 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| AU2023269801A1 (en) * | 2022-05-11 | 2024-09-12 | Slate Bio, Inc. | Compositions comprising truncated interleukin-33 and interleukin-2 |
| WO2025106677A1 (en) * | 2023-11-15 | 2025-05-22 | Slate Bio, Inc. | Bifunctional il-2 and il-33 proteins for treating autoimmune disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| ATE407697T1 (de) * | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| US20050089517A1 (en) | 2003-09-23 | 2005-04-28 | Shames Richard S. | Treatment of respiratory diseases with anti-IL-2 receptor antibodies |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JP2015528003A (ja) | 2012-07-13 | 2015-09-24 | ザイムワークス，インコーポレイテッド | 抗ｃｄ３構築物を含む二重特異性の非対称ヘテロ二量体 |
| KR102545617B1 (ko) * | 2012-11-28 | 2023-06-20 | 자임워크스 비씨 인코포레이티드 | 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도 |
| DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| US9840545B2 (en) | 2013-09-20 | 2017-12-12 | University Of Virginia Patent Foundation | Fusion protein comprising interleukin-2 and interleukin-33 |
| HRP20190028T1 (hr) | 2014-02-06 | 2019-02-22 | F. Hoffmann - La Roche Ag | Interleukin-2 fuzijski proteini i njihove primjene |
| PT3172227T (pt) | 2014-07-21 | 2019-12-06 | Delinia Inc | Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis |
| JP7228515B2 (ja) | 2016-12-13 | 2023-02-24 | デリニア，インコーポレーテッド | 多価制御性ｔ細胞調節因子 |
-
2017
- 2017-12-13 JP JP2019531303A patent/JP7228515B2/ja active Active
- 2017-12-13 WO PCT/US2017/066163 patent/WO2018112069A1/en not_active Ceased
- 2017-12-13 CN CN201780076808.XA patent/CN110177564A/zh active Pending
- 2017-12-13 RU RU2019121902A patent/RU2769871C2/ru active
- 2017-12-13 AU AU2017378308A patent/AU2017378308A1/en not_active Abandoned
- 2017-12-13 KR KR1020197020221A patent/KR20190094222A/ko not_active Ceased
- 2017-12-13 CA CA3044416A patent/CA3044416A1/en not_active Abandoned
- 2017-12-13 BR BR122020025384-3A patent/BR122020025384B1/pt active IP Right Grant
- 2017-12-13 BR BR112019011799-7A patent/BR112019011799B1/pt not_active IP Right Cessation
- 2017-12-13 MX MX2019007002A patent/MX381276B/es unknown
- 2017-12-13 EP EP17881187.3A patent/EP3554525A4/en not_active Withdrawn
- 2017-12-13 US US15/840,721 patent/US10472405B2/en active Active
-
2019
- 2019-06-13 MX MX2021004007A patent/MX2021004007A/es unknown
- 2019-10-17 US US16/655,544 patent/US11059877B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501550A5 (cg-RX-API-DMAC7.html) | ||
| JP6849600B6 (ja) | キメラ抗原受容体、組成物及び方法 | |
| RU2710730C2 (ru) | Конструкции мультиспецифичных антител | |
| RU2019121902A (ru) | Поливалентные модуляторы регуляторных t-клеток | |
| JP7663977B2 (ja) | 抗ｐｄ―ｌ１抗体およびその用途 | |
| JP6231007B2 (ja) | Ｂｃｍａおよびｃｄ３に対する結合分子 | |
| ES2199941T3 (es) | Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j. | |
| JP2019507589A5 (cg-RX-API-DMAC7.html) | ||
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| JP2019532996A5 (cg-RX-API-DMAC7.html) | ||
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| CN115925958A (zh) | 特异性结合mage-a的抗原结合蛋白 | |
| JP2019129830A (ja) | Ｂｃｍａおよびｃｄ３に対する結合分子 | |
| JP7652690B2 (ja) | アゴニスト性腫瘍壊死因子受容体スーパーファミリーポリペプチド | |
| JP2015518479A5 (cg-RX-API-DMAC7.html) | ||
| EA012622B1 (ru) | Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки | |
| JP2018537421A5 (cg-RX-API-DMAC7.html) | ||
| CA3190417A1 (en) | Compositions and methods related to receptor pairings | |
| JP2015511219A (ja) | 標的変異体αヘリックスバンドルサイトカイン | |
| JP2017527272A5 (cg-RX-API-DMAC7.html) | ||
| CN112375145B (zh) | 人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法 | |
| JP2016524592A5 (cg-RX-API-DMAC7.html) | ||
| JP2019503686A5 (cg-RX-API-DMAC7.html) | ||
| EP3368569B1 (en) | Polypeptides against il-23 |